refractory celiac
Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.
When the diet stops working — persistent gut destruction despite a strict gluten-free diet, affecting ~1.5% of celiac patients.
Refractory celiac disease is defined as the persistence of histological villous-atrophy (confirmed by biopsy) and ongoing nutritional or symptomatic disease despite strict adherence to a gluten-free-diet for at least 12 months, after excluding other causes. It is a rare but serious complication with high morbidity and mortality.
Two Distinct Subtypes
RCD is divided into two types based on the phenotype of intraepithelial lymphocytes (IELs) — a distinction that completely changes prognosis and treatment:
| RCD Type 1 | RCD Type 2 | |
|---|---|---|
| IEL phenotype | Normal surface markers | Aberrant — lose CD3/CD8, gain intracellular CD3 |
| Prevalence among RCD | More common | Less common |
| Prognosis | Relatively better | Poor — high mortality |
| EATL risk | Low but not zero | High — now best understood as a low-grade intraepithelial lymphoma / pre-lymphomatous state |
| Treatment | Open-capsule budesonide first-line; azathioprine/other immunomodulators in selected cases | Open-capsule budesonide first-line; cladribine-based or transplant strategies in selected patients |
| 5-year survival | Generally favorable | Historically poor; older series often ~44–58% |
| 5-year EATL progression risk | Low | Often reported around 33–52% |
The RCD Type 2 Problem
RCD type 2 is driven by il-15 and is now best thought of as a low-grade intraepithelial lymphoma rather than just severe inflammation. Under sustained IL-15 stimulation, IELs gradually lose their normal immune identity and acquire abnormal characteristics. This population of aberrant IELs:
- Has reduced surface CD3/CD8 expression (normally used to identify T cells)
- Gains intracellular CD3 (used to distinguish type 2 from type 1 in biopsy)
- Is clonally expanding — a hallmark of pre-malignancy
- Can progress to enteropathy-associated T-cell lymphoma (EATL)
Distinguishing RCD from NRCD
Before diagnosing RCD, all causes of non-responsive celiac disease (NRCD) must be excluded:
- Unintentional gluten ingestion
- sibo, giardiasis, pancreatic insufficiency
- Microscopic colitis, Crohn's disease
- Drug-induced enteropathy (olmesartan, mycophenolate, PPIs)
- Collagenous sprue, autoimmune enteropathy
Treatment
Type 1 RCD:
- Open-capsule budesonide (preferred) or prednisone — first-line
- Azathioprine / thioguanine / selected immunomodulators in difficult cases
- Nutritional support (often requires enteral or parenteral nutrition)
- Careful longitudinal follow-up because chronic inflammation still carries risk
Type 2 RCD:
- Open-capsule budesonide often improves symptoms and histology, but may not eliminate the neoplastic IEL clone
- Cladribine / purine-analog approaches in selected centers
- Autologous stem cell transplant — for selected budesonide-refractory patients, often younger/fit enough for escalation in specialist centers
- Anti-IL-15 approaches have been tested, but early results were disappointing for mucosal healing
- JAK inhibitors are under investigation because many RCD type 2 lesions activate the JAK/STAT pathway
A 2023 RCD-focused review usefully sharpens the practical hierarchy:
- budesonide first for both subtypes
- thiopurine-style maintenance makes more sense in RCD-I than RCD-II
- cladribine / transplant escalation belongs mainly to difficult RCD-II pathways
- alternative options like mesalamine, infliximab, or IL-10 remain much less established
Related Concepts
intraepithelial-lymphocytes | il-15 | eatl | villous-atrophy | non-responsive-celiac | gluten-free-diet | il-15-inhibitors | marsh-classification
Source Basis
Current synthesis incorporates:
raw/1-s2.0-S0016508524003603-main.pdf(Advances in Nonresponsive and Refractory Celiac Disease, 2024), which strongly frames RCD type 2 as a low-grade intraepithelial lymphoma and highlights open-capsule budesonide as current first-line therapy for both subtypesraw/jcm-14-06934.pdf(Management Strategy for Non-Responsive and Refractory Celiac Disease in Adults, 2025), which reinforces the hierarchical workup, specialist-center management, and the distinction between RCD-I and RCD-IIraw/ijms-24-12800.pdf(Old and New Adjunctive Therapies in Celiac Disease and Refractory Celiac Disease: A Review, 2023), which is especially useful for older-drug treatment hierarchy, budesonide response patterns, and how differently RCD-I and RCD-II behave under thiopurine-style therapyraw/nihms176819.pdf(Classification and Management of Refractory Celiac Disease, 2010), parked as historical classification and management backgroundraw/f1000research-5-9741.pdf(Approach to patients with refractory celiac disease, 2016), parked as additional clinical-review background